Subscribe
The latest psychology and neuroscience discoveries.
My Account
  • Mental Health
  • Social Psychology
  • Cognitive Science
  • Psychopharmacology
  • Neuroscience
  • About
No Result
View All Result
PsyPost
PsyPost
No Result
View All Result
Home Exclusive Mental Health Borderline Personality Disorder

Psychedelics could make mental health worse in people with a personality disorder

by Pouya Movahed Rad
May 4, 2024
in Borderline Personality Disorder, Psychedelic Drugs
Share on TwitterShare on Facebook
Stay on top of the latest psychology findings: Subscribe now!

The interest in psychedelics is growing both in scientific circles and among the public. These are powerful substances capable of altering perception, mood and various mental processes. They also show promise for treating a wide range of mental health disorders.

However, for their use to be safe and effective, it’s important to understand how they interact with different mental health conditions. This is especially true for personality disorders.

A personality disorder is a type of mental disorder involving rigid and unhealthy patterns of thinking, functioning and behaving, which significantly affect a person’s life. Understanding their interaction with psychedelics is crucial. These substances can deeply influence mental states. They can worsen or improve symptoms in ways unique to these disorders.

In a recent study, researchers at Imperial College London investigated the complex relationship between psychedelics and mental health, highlighting the potential risks for people with personality disorders.

The study collected self-reported data from 807 people who used psychedelics in various settings, from recreational to therapeutic. They measured participants’ mental wellbeing before and after using psychedelics using a scale called the Warwick-Edinburgh mental wellbeing scale. The researchers considered it a meaningful drop in mental health if someone’s happiness and wellbeing fell more than what was typical for most people in the study.

The researchers specifically looked at those who had negative experiences while on psychedelics. They found that only 16% of all participants reported an overall negative response. But a significant portion of these negative experiences (31%) were reported by people with a history of personality disorders.

However, the study has several limitations, including the reliance on self-reported data, the small number of participants and a 56% dropout rate. All of these factors would have skewed the results.

Other limitations include the lack of a control group (people given a placebo or standard treatment) for comparison. Additionally, there were variations in the types and dosages of psychedelics used.

The study’s method of participant selection could also lead to biased results. And lumping different personality disorders together might overlook specific risks associated with each.

Different responses

Various personality disorders might respond differently to psychedelics. For instance, people with histrionic personality disorder (excessive attention-seeking and emotional overreaction) or borderline personality disorder (emotional instability, intense relationships and fear of abandonment) might feel worse or more unstable.

And those with schizotypal personality disorder (social anxiety, odd beliefs and eccentric behaviour) could become more paranoid.

People with narcissistic personality disorder (excessive self-importance, lack of empathy, and need for admiration) may struggle with the self-reflective nature of psychedelics because they often have a hard time handling criticism.

Considering the study’s notable limitations, we must approach its findings with some scepticism. Yet the study does recognise the potential benefits of psychedelics for mental health, stressing the need for careful screening for personality disorders.

Using psychedelics safely and effectively requires a personalised approach. This is especially true for vulnerable people. This highlights the importance of refining psychedelic therapy to make it safe and effective for all.

As we explore the expanding territory of psychedelic therapy, it’s vital to understand how these substances interact with mental health conditions – including personality disorders.

We must use more rigorous methods, such as controlled trials to compare psychedelics to standard treatments or a placebo. Personality disorders should also be verified via professional evaluation, not just self-reports. And, finally, psychedelic doses need to be uniform in order to reliably assess their therapeutic effect.The Conversation

 

This article is republished from The Conversation under a Creative Commons license. Read the original article.

RELATED

Exposure to heavy metals is associated with higher likelihood of ADHD diagnosis
Depression

Non-hallucinogenic psychedelic analog boosts brain plasticity in an unexpected way

September 18, 2025
Psychedelic mushrooms and quiet quitting: Psilocybin use tied to working fewer overtime hours
Depression

Psilocybin therapy linked to lasting depression remission five years later

September 11, 2025
Extraverts show faster, stronger, and more patterned emotional reactions
Depression

Single dose of psilocybin linked to lasting symptom relief in treatment-resistant depression

September 8, 2025
Largest-ever survey on ayahuasca highlights links to better mental health and wellbeing
Mental Health

Ibogaine treatment linked to changes in brain rhythms and psychiatric improvements in veterans with traumatic brain injury

September 6, 2025
Neuroscientists just rewrote our understanding of psychedelics with a groundbreaking receptor-mapping study
Ayahuasca

Neuroscientists just rewrote our understanding of psychedelics with a groundbreaking receptor-mapping study

September 1, 2025
Surprising link found between aesthetic chills and political extremism
Anxiety

Single dose of psilocybin provides lasting relief from depression and anxiety in cancer patients

August 27, 2025
Scientists uncover biological pathway that could revolutionize anxiety treatment
MDMA

Psilocybin and MDMA may reset fear-related brain-immune signaling, scientists find

August 25, 2025
Neuroscience research shows psychedelics plus psychotherapy can trigger rapid brain changes
Ayahuasca

Near-death visions and DMT trips share eerie similarities — but key differences set them apart

August 17, 2025

STAY CONNECTED

LATEST

Artificial intelligence reveals hidden facial cues of mild depression

Veterans who develop excessive daytime sleepiness face increased risk of death

Non-hallucinogenic psychedelic analog boosts brain plasticity in an unexpected way

New research finds the cumulative weight of social hardship across a lifespan shapes the aging brain

U.S. sees 5.7 million more childless women than expected, fueling a “demographic cliff”

AI hate speech detectors show major inconsistencies, new study reveals

New study sheds light on how sexual self-disclosure relates to relationship quality

Brain scan study connects parahippocampal cortex thinning with depression and neuroticism

         
       
  • Contact us
  • Privacy policy
  • Terms and Conditions
[Do not sell my information]

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

Subscribe
  • My Account
  • Cognitive Science Research
  • Mental Health Research
  • Social Psychology Research
  • Drug Research
  • Relationship Research
  • About PsyPost
  • Contact
  • Privacy Policy